- Home
- VLY vs RYTM Comparison
VLY vs RYTM Comparison
Compare VLY & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VLY | RYTM |
|---|---|---|
| Founded | 1927 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9B | 6.4B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | VLY | RYTM |
|---|---|---|
| Price | $13.46 | $108.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $13.69 | ★ $129.92 |
| AVG Volume (30 Days) | ★ 8.3M | 575.0K |
| Earning Date | 01-29-2026 | 02-25-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | ★ 46.38 | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $1,844,204,000.00 | $174,334,000.00 |
| Revenue This Year | $21.35 | $47.98 |
| Revenue Next Year | $8.04 | $56.07 |
| P/E Ratio | $13.01 | ★ N/A |
| Revenue Growth | 21.48 | ★ 54.92 |
| 52 Week Low | $7.48 | $45.91 |
| 52 Week High | $13.16 | $122.20 |
Technical Indicators
Market Signals| Indicator | VLY | RYTM |
|---|---|---|
| Relative Strength Index (RSI) | 71.68 | 52.33 |
| Support Level | $11.64 | $100.59 |
| Resistance Level | $12.97 | $111.25 |
| Average True Range (ATR) | 0.38 | 4.88 |
| MACD | 0.11 | 0.53 |
| Stochastic Oscillator | 96.04 | 55.24 |
Price Performance
Historical ComparisonAbout VLY Valley National Bancorp
Valley National Bancorp is a bank holding company that offers a full suite of national and regional banking solutions through various commercial, private banking, retail, insurance, and wealth management financial services products. It provides personalized service and customized solutions to assist its customers with their financial service needs. The group also offers niche financial services, including loan and deposit products for homeowners associations, cannabis-related business banking, and venture banking, which offers nationally. It manages its business operations under operating segments consisting of Consumer Banking; Commercial Banking; and Treasury and Corporate Other. The group generates the majority of its revenue from the Commercial Banking Segment.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.